ZI Factor
ZI-Factor: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. Drug interactions
- 12. Analogs
- 13. Terms and conditions of storage
- 14. Terms of dispensing from pharmacies
- 15. Reviews
- 16. Price in pharmacies
Latin name: ZI-Factor
ATX code: J01FA10
Active ingredient: Azithromycin (Azithromycinum)
Manufacturer: OJSC "Veropharm" (Russia)
Description and photo update: 18.10.2018
Prices in pharmacies: from 110 rubles.
Buy
ZI-Factor is an antibiotic of the azalide group.
Release form and composition
Forms of release of ZI-Factor:
- coated tablets: oblong, biconvex, the color of the shell is light pink, two layers are visible in the cross section, the layer inside is almost white or white (3 tablets each in a blister strip or a jar of light-protective glass, 1 package or a can in a pack of cardboard);
- capsules: gelatinous hard, size No. 0, color - white. The content of the capsule is a mixture of granules and powder of white with a yellowish tinge or white (6 or 10 capsules in a blister strip or 10 capsules in a jar or bottle, 1 can, bottle or packaging in a cardboard box).
Composition of 1 tablet:
- active substance: azithromycin - 500 mg;
- auxiliary components: hydroxypropyl methylcellulose (hypromellose), titanium dioxide, polyvinylpyrrolidone (povidone), talc, polysorbate-80, carmoisine (azorubin dye).
Composition of 1 capsule:
- active substance: azithromycin - 250 mg;
- auxiliary components: milk sugar (lactose), lactopress (anhydrous lactose), corn starch, polyvinylpyrrolidone (povidone), sodium lauryl sulfate, colloidal silicon dioxide (aerosil), magnesium stearate;
- capsule: titanium dioxide, propyl parahydroxybenzoate, gelatin, acetic acid, methyl parahydroxybenzoate.
Pharmacological properties
Pharmacodynamics
ZI-Factor is a broad-spectrum antibiotic. It is a representative of the subgroup of macrolide antibiotics - azalides. It has a bactericidal effect when high concentrations occur in the focus of inflammation.
Sensitive to azithromycin:
- gram-positive cocci: St. pyogenes, St. Viridans, St. agalactiae, Streptococcus pneumoniae, group G and CF streptococci, Staphylococcus aureus;
- gram-negative bacteria: Haemophilus influenzae, Bordetella pertussis, B. parapertussis, H. ducreyi, Campylobacter jejuni, Gardnerella vaginalis, Neisseria gonorrhoeae, Moraxella catarrhalis, Legionella pneumophila;
- some anaerobic microorganisms: Bacteroides bivius, Clostridium perfringens, Peptostreptococcus spp;
- other microorganisms: Chlamydia trachomatis, Treponema pallidum, Borrelia burgdorferi, Ureaplasma urealyticum, Mycoplasma pneumoniae.
Against gram-positive bacteria that are resistant to erythromycin, azithromycin is inactive.
Pharmacokinetics
Absorption from the gastrointestinal tract is fast, which is determined by the lipophilicity of azithromycin and its stability in an acidic environment. 2.5 (or slightly more) hours after taking 500 mg (1 tablet or 2 capsules), the maximum concentration of azithromycin in blood plasma is reached - 0.4 mg / l. Bioavailability - 37%. Azithromycin actively penetrates into the organs and tissues of the urogenital tract (especially the prostate gland), respiratory tract, soft tissues and skin. In tissues, the concentration is 10-50 times higher than in blood plasma, and the half-life is longer, which is due to the low binding of azithromycin to blood plasma proteins, as well as the ability of the substance to penetrate eukaryotic cells and concentrate in the environment with low pH surrounding the lysosome. This determines a high plasma clearance and a volume of distribution of 31.1 l / kg. For the elimination of intracellular pathogens, the ability of azithromycin to concentrate mainly in lysosomes is especially important. It was revealed that phagocytes transport azithromycin to the sites of infection, where it is released due to phagocytosis. The concentration of azithromycin in the foci of infection is 24–34% higher than in healthy tissues and correlates with the degree of inflammatory edema. Regardless of the high concentration in phagocytes, azithromycin practically does not affect their function. Azithromycin in bactericidal concentrations in the focus of inflammation remains for 5-7 days after the last dose was taken [this circumstance made it possible to develop short courses of treatment (3-5 days)]. Demethylated in the liver, the resulting metabolites are inactive.
The elimination of azithromycin from blood plasma takes place in two stages: in the interval from 8 to 24 hours after taking the drug, the half-life period is 14–20 hours, in the interval from 24 to 72 hours - 41 hours, which makes it possible to use the drug once a day.
Indications for use
- borreliosis (Lyme disease) - for the treatment of the initial stage (erythema migrans); infections of the upper respiratory tract and upper respiratory tract (sinusitis, otitis media, tonsillitis, tonsillitis, pharyngitis);
- infections of the skin and soft tissues (impetigo, secondarily infected dermatoses, erysipelas);
- lower respiratory tract infections (bronchitis, atypical and bacterial pneumonia);
- infectious and inflammatory diseases caused by microorganisms that are sensitive to the drug.
Additionally for tablets:
- infections of the urogenital tract (cervicitis and / or uncomplicated urethritis);
- diseases of the duodenum and stomach associated with Helicobacter Pylori (as a combination therapy);
- scarlet fever.
An additional indication for the use of ZI-Factor in the form of capsules are urinary tract infections caused by Chlamydia trachomatis (cervicitis, urethritis).
Contraindications
- hypersensitivity to the components of the drug;
- renal / hepatic impairment;
- period of breastfeeding;
- age up to 1 year - for tablets, up to 12 years (weighing less than 45 kg) - for capsules.
Additional contraindications for ZI-Factor capsules are:
- a one-time reception with dihydroergotamine and ergotamine;
- lack of lactase;
- genetic intolerance to galactose;
- glucose-galactose malabsorption.
Instructions for the use of ZI-Factor: method and dosage
The antibiotic ZI-Factor is applied orally (by mouth) 1 time per day, 1 hour before meals or 2 hours after meals.
Recommended daily intake for adults:
- infections of the upper and lower respiratory tract: 500 mg, duration of treatment - 3 days;
- acute urinary tract infections: 1000 mg once;
- infections of the skin, soft tissues, Lyme disease and erythema migrans: 1000 mg on the first day, then 500 mg for 5 days;
- peptic ulcer of the duodenum and stomach associated with Helicobacter pylori: 1000 mg for 3 days with joint anti-Helicobacter pylori therapy.
For children, the daily dose is prescribed at the rate of 10 mg per 1 kg for 3 days, or on the first day - 10 mg per 1 kg, then 5-10 mg per 1 kg for 3 days (course dose is 30 mg / kg).
When treating erythema migrans in children, the daily dose is 20 mg per 1 kg on the first day and 10 mg per 1 kg for the next 4 days. The duration of the course is 5 days.
In patients with impaired renal function (CC> 40 ml / min), there is no need to adjust the dose.
Side effects
- digestive system: nausea, vomiting, diarrhea / constipation, cholestatic jaundice, abdominal pain, indigestion, anorexia, flatulence, dyspepsia, melena, increased activity of hepatic transaminases; in children - constipation, anorexia, gastritis;
- cardiovascular system: chest pain, palpitations, arrhythmias, increased QT interval;
- circulatory system: neutropenia, thrombocytopenia;
- sense organs: tinnitus, disturbances in the perception of smell and taste, reversible hearing impairment up to deafness (with prolonged use of high doses);
- nervous system: headache, dizziness, drowsiness / insomnia, aggressiveness; in children - headache (in the treatment of otitis media), hyperkinesia, neurosis, anxiety, sleep disturbance;
- genitourinary system: nephritis, vaginal candidiasis;
- allergic reactions: itching, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity, rash, Quincke's edema.
Overdose
Symptoms of an overdose of the antibiotic ZI-Factor are: nausea, vomiting, diarrhea, temporary hearing loss.
When these symptoms appear, symptomatic treatment is prescribed.
special instructions
It is required to observe a break of 2 hours when using antacids together with ZI-Factor.
After discontinuation of therapy, hypersensitivity reactions in some patients may persist, which requires specific treatment under the supervision of a specialist.
If you skip taking one dose of the drug, the missed dose should be taken as soon as possible, and the subsequent ones - with an interval of 24 hours.
With azithromycin therapy, it is possible to add superinfection (including fungal).
ZI-Factor is active against streptococcal infection, but ineffective for the prevention of acute rheumatic fever.
Influence on the ability to drive vehicles and complex mechanisms
Azithromycin does not affect the ability to drive machinery and vehicles.
Application during pregnancy and lactation
Azithromycin should be used in pregnant women only when the expected benefit to the mother outweighs the possible risk to the fetus. During the period of therapy, breastfeeding should be discontinued.
Pediatric use
According to the instructions, ZI-Factor is contraindicated under the age of 1 year (tablets), up to 12 years old with a weight of less than 45 kg (capsules).
Drug interactions
- antacids (aluminum and magnesium), ethanol and food: slow down and reduce the absorption of the drug;
- warfarin and azithromycin: the anticoagulant effect may be enhanced;
- digoxin: increases the concentration of the latter;
- ergotamine and dihydroergotamine: increase the toxic effect;
- triazolam: ZI-Factor reduces clearance and increases the pharmacological action of triazolam;
- drugs subject to microsomal oxidation (carbamazepine, disopyramide, terfenadine, cyclosporine, valproic acid, hexobarbital, ergot alkaloids, phenytoin, bromocriptine, oral hypoglycemic agents, theophylline and other xanthine derivatives, methylopredinodine derivatives, non-counting antibodies) microsomal oxidation in hepatocytes with azithromycin slows down their excretion, increases plasma concentration and toxicity;
- tetracycline and chloramphenicol: enhance the effectiveness of the drug;
- lincosamides: weaken the effectiveness of the drug;
- terfenadine and macrolide antibiotics: cause arrhythmia and prolongation of the QT interval;
- ergotamine and dihydroergotamine: possible manifestation of their toxic effect;
- heparin: incompatible with the drug.
Azithromycin does not affect the concentration of didanosine, carbamazepine, rifabutin and methylprednisolone in blood plasma when used in combination. It is impossible to exclude the effect of azithromycin (when administered orally) on the concentration of triazolam, cimetidine, indinavir, efavirenz, fluconazole, midazolam, sulfamethoxazole / trimethoprim in blood plasma when used in combination.
ZI-Factor has no effect on theophylline pharmacokinetics, however, with simultaneous use with other macrolides in the blood plasma, the concentration of theophylline may increase.
Since there is a possibility of inhibition of the CYP3A4 isoenzyme by azithromycin in parenteral form when administered simultaneously with terfenadine, ergot alkaloids, cisapride, cycloserine, pimozide, astemizole, quinidine and other drugs, the metabolism of which occurs with the participation of this enzyme, it is necessary to take into account the possibility of such interaction when prescribing inside.
When used in combination, azithromycin does not affect the pharmacokinetic parameters of zidovudine and its metabolite, glucuronide. Nevertheless, the concentration of its active metabolite, phosphorylated zidovudine, increases in mononuclear cells of peripheral vessels.
Analogs
ZI-Factor analogs are: Azibiot, Azivok, Azidrop, Azimycin, Azitral, Azitrox, Azithromycin, Azithromycin Zentiva, Azithromycin Sandoz, Azithromycin Forte-OBL, Azithromycin-OBL, Azithromycin-LEXVM, Forteodzitromycin-AzitR, Zitnob, Zitrolide, Zitrolide forte, Zitrocin, Sumaclid, Sumamed, Sumamed forte, Sumamox, Tremak-Sanovel, Hemomycin, Ecomed.
Terms and conditions of storage
Store in a dry place at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Shelf life:
- tablets - 3 years;
- capsules - 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews of ZI-Factor
Reviews about the ZI-Factor are mostly positive. However, some patients report side effects such as anxiety and upset stools.
Price for ZI-Factor in pharmacies
The price of ZI-Factor in tablets is approximately 184 rubles, in capsules - 196 rubles per pack.
ZI-Factor: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Zi-Factor 250 mg capsule 6 pcs. 110 RUB Buy |
|
Zi-Factor 500 mg film-coated tablets 3 pcs. RUB 150 Buy |
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
